Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| NS Georgia | Pharma | 11.5% | 44th pct | 110 |
| Pulparmi | Pharma | 8.1% | 35th pct | 110 |
| Med Treideri | Pharma | 1.3% | 17th pct | 110 |
| Maksparma | Pharma | — | no FY data | 110 |
| Anshen Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2023 (4 of 5).
| Ratio — FY 2024 | Med Treideri | Pulparmi | NS Georgia | Maksparma | Anshen Pharma |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 42.7% | 22.7% | 33.7% | — | — |
| EBITDA Margin | 1.3% | 8.1% | 11.5% | — | — |
| EBITDAR | 50 | 148 | 235 | — | — |
| EBITDAR Margin | 2.9% | 8.6% | 14.1% | — | — |
| EBIT Margin | 1.1% | 7.9% | 9.9% | — | — |
| Net Profit Margin | -1.2% | 7.9% | 8.3% | — | — |
| Operating Expense % of Sales | 41.4% | 14.6% | 22.1% | — | — |
| Returns | |||||
| Return on Assets (ROA) | -1.0% | 39.4% | 4.2% | — | — |
| Return on Equity (ROE) | -2.7% | 127.8% | 4.6% | — | — |
| ROIC [EBIT / Invested Capital] | 2.1% | 137.9% | 6.4% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 13.6% | 0.0% | 0.0% | — | — |
| Debt-to-Equity | 0.37x | 0.00x | 0.00x | — | — |
| Debt-to-EBITDA | 12.01x | 0.00x | 0.00x | — | — |
| Equity-to-Assets | 37.1% | 30.8% | 91.4% | — | — |
| Net Debt | 214 | -8 | -426 | — | — |
| Cash & Equivalents | 60 | 8 | 426 | — | — |
| Total Debt | 274 | N/A | N/A | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.01x | 1.37x | 10.73x | — | — |
| Quick Ratio | 0.01x | 1.37x | 10.73x | — | — |
| Cash Ratio | 0.00x | 0.03x | 1.50x | — | — |
| Total Current Assets | 1,963 | 329 | 3,051 | — | — |
| Total Current Liabilities | 196,299 | 240 | 284 | — | — |
| Inventory | N/A | N/A | N/A | — | — |
| Trade Receivables | 336 | 225 | 1,630 | — | — |
| Trade Payables | 489 | 240 | 284 | — | — |
| Net Working Capital | -194,336 | 89 | 2,766 | — | — |
| Net Working Capital % of Revenue | -11222.0% | 5.2% | 165.6% | — | — |
| Trade Working Capital | -153 | -14 | 1,345 | — | — |
| Trade Working Capital % of Revenue | -8.8% | -0.8% | 80.5% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | — | — |
| Receivables Turnover | 5.15x | 7.68x | 1.03x | — | — |
| Days Sales Outstanding (DSO) | 70.8 | 47.6 | 356.1 | — | — |
| Payables Turnover | 2.03x | 5.57x | 3.90x | — | — |
| Days Payable Outstanding (DPO) | 179.7 | 65.5 | 93.7 | — | — |
| Cash Conversion Cycle | -108.9 days | -17.9 days | 262.4 days | — | — |
| Asset Turnover | 0.86x | 4.99x | 0.51x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | -130 | N/A | — | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | -130 | N/A | — | — |
| Cash Conversion (OCF / EBITDA) | N/A | -92.9% | N/A | — | — |
| Dividends Declared | N/A | N/A | N/A | — | — |
| Dividend Payout Ratio | N/A | N/A | N/A | — | — |